ePrints

Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients

Lookup NU author(s): Dr Samuel Moses

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Hepatitis B virus (HBV) is a partially double stranded DNA virus that can integrate into host cell chromosomes as covalently closed circular DNA forms. HBV reactivation following hematopoietic stem cell transplantation in recipients with evidence of past HBV exposure, as well as exacerbation of a current HBV infection in HBV carrier recipients, secondary to chemotherapy and post-transplant immunosuppression that affect both humoral and cell-mediated control of HBV infection, are well documented in the literature. Management options include HBV-DNA screening and antiviral prophylaxis. Nucleos(t)ide analogues have been used at the start of chemotherapy and pretransplantation, with the course continuing for 6 months. However, depending on the serum HBV-DNA level, the antiviral agent might be given until a therapeutic end point is reached.

Publication metadata

Author(s): Moses SE, Lim Z, Zuckerman MA

Publication type: Review

Publication status: Published

Journal: Expert Review of Anti-infective Therapy

Year: 2011

Volume: 9

Issue: 10

Pages: 891-899

Print publication date: 01/10/2011

ISSN (print): 1478-7210

ISSN (electronic): 1744-8336

URL: http://dx.doi.org/10.1586/eri.11.105

DOI: 10.1586/eri.11.105

PubMed id: 21973301

Share